Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02689440 · ClinicalTrials.gov registry record · Phase 2
Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia
A Phase 2 study of Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 155
- Enrollment target
- 1
- Study location
NCT02689440: Active Phase 2 study of Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia, sponsored by M.D. Anderson Cancer Center.
NCT02689440 is a Phase 2 study of Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 155 participants, above the 57-participant average among 7 other Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive trials with a reported enrollment target (172% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02689440, a Phase 2 study of Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 155 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well dasatinib and venetoclax work in treating patients with Philadelphia chromosome positive or BCR-ABL1 positive early chronic phase chronic myelogenous leukemia. Dasatinib and venetoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Primary Outcome
MMR estimates will be presented with 95% credible intervals. MMR and patient and clinical characteristics will be examined by Wilcoxon's rank sum test or Fisher's exact test.
Conditions Studied
Interventions
- DRUG Venetoclax
- OTHER Laboratory Biomarker Analysis
- DRUG Dasatinib
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2016-02-19 |
| Est. Completion | 2040-12-31 |
| Phase | Phase 2 |
What the registry record for NCT02689440 still lists
NCT02689440 is an interventional study that assigns participants to a tested intervention. The registered 155 participants enrollment target is mid-sized for trials with a published cap, above the 57-participant average among 7 other Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive trials with a reported enrollment target (172% higher).
The record links to 2 conditions, with Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive appearing as the primary indexed condition, and to 3 interventions - of which Venetoclax is the first listed.
NCT02689440 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02689440 about?
NCT02689440 is a clinical study titled "Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia". This phase II trial studies how well dasatinib and venetoclax work in treating patients with Philadelphia chromosome positive or BCR-ABL1 positive early chronic phase chronic myelogenous leukemia. Dasatinib and venetoclax may stop the growth of tumor cells by blocking some of the enzymes needed for ...
What is the current status of trial NCT02689440?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 155 participants. The study started on 2016-02-19. Estimated completion is 2040-12-31.
What conditions does trial NCT02689440 study?
This clinical trial studies the following conditions: Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia.
What interventions are being tested in trial NCT02689440?
The interventions under investigation include: Venetoclax (DRUG), Laboratory Biomarker Analysis (OTHER), Dasatinib (DRUG).
Who is sponsoring clinical trial NCT02689440?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02689440 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib
RECRUITING · Phase 2
-
Personalized NK Cell Therapy in CBT
RECRUITING · Phase 2
-
Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation
ACTIVE NOT RECRUITING · Phase 2
-
Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia
ACTIVE NOT RECRUITING · Phase 2
-
Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
ACTIVE NOT RECRUITING · Phase 2
-
Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03223610 · 155 participants · Phase 1
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
- NCT05072483 · 155 participants
Natural History Study of CADASIL
- NCT05086497 · 155 participants · NA
WBSI Guided Personalized Delivery of TTFields
- NCT05412069 · 155 participants · NA
Trial to Evaluate Fecobionics in Fecal Incontinence (FI) (NORMAL and ABNORMAL-FI)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI